EAEsther Aguilar

Esther Aguilar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Esther Aguilar has a total of 85 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • LKB1 deficiency in T cells promotes the development of gastrointestinal polyposis

    by M. C. Poffenberger, A. Metcalfe-Roach, E. Aguilar, J. Chen, B. E. Hsu, A. H. Wong, R. M. Johnson, B. Flynn, B. Samborska, E. H. Ma, et al.

    Inflammation promotes gut polyposis: Peutz–Jeghers Syndrome (PJS) causes benign polyps in the gut and a higher risk of several cancers caused by mutations in the tumor suppressor gene STK11 , which encodes liver kinase B1 (LKB1). LKB1's role in this disease is thought to be related to its tumor suppressor function. Now, Poffenberger et al. show that the T cell–specific heterozygous deletion of Stk11 is sufficient to reproduce PJS symptoms in mice (see the Perspective by Hollstein and Shaw). Polyps in mice and humans are characterized by immune cell infiltration, enhanced STAT3 signaling, and increased levels of inflammatory cytokines such as interleukin-6 (IL-6). Targeting STAT3 signaling, IL-6, or T cells ameliorated the polyps, suggesting potential therapies for this disease. Science , this issue p. 406 ; see also p. 332


  • Open Access

    Model-driven discovery of long-chain fatty acid metabolic reprogramming in heterogeneous prostate cancer cells

    by Igor Marín De Mas, Esther Aguilar, Erika Zodda, Cristina Balcells, Silvia Marin, Guido Dallmann, Timothy M Thomson, Balázs Papp, Marta Cascante

    Epithelial-mesenchymal-transition promotes intra-tumoral heterogeneity, by enhancing tumor cell invasiveness and promoting drug resistance. We integrated transcriptomic data for two clonal subpopulations from a prostate cancer cell line (PC-3) into a genome-scale metabolic network model to explore their metabolic differences and potential vulnerabilities. In this dual cell model, PC-3/S cells express Epithelial-mesenchymal-transition markers and display high invasiveness and low metastatic potential, while PC-3/M cells present the opposite phenotype and higher proliferative rate. Model-driven analysis and experimental validations unveiled a marked metabolic reprogramming in long-chain fatty acids metabolism. While PC-3/M cells showed an enhanced entry of long-chain fatty acids into the mitochondria, PC-3/S cells used long-chain fatty acids as precursors of eicosanoid metabolism. We suggest that this metabolic reprogramming endows PC-3/M cells with augmented energy metabolism for fast proliferation and PC-3/S cells with increased eicosanoid production impacting angiogenesis, cell adhesion and invasion. PC-3/S metabolism also promotes the accumulation of docosahexaenoic acid, a long-chain fatty acid with antiproliferative effects. The potential therapeutic significance of our model was supported by a differential sensitivity of PC-3/M cells to etomoxir, an inhibitor of long-chain fatty acid transport to the mitochondria. The coexistence within the same tumor of a variety of subpopulations, featuring different phenotypes (intra-tumoral heterogeneity) represents a challenge for diagnosis, prognosis and targeted therapies. In this work, we have explored the metabolic differences underlying tumor heterogeneity by building cell-type-specific genome-scale metabolic models that integrate transcriptome and metabolome data of two clonal subpopulations derived from the same prostate cancer cell line (PC-3). These subpopulations display either highly proliferative, cancer stem cell (PC-3/M) or highly invasive, epithelial-mesenchymal-transition-like phenotypes (PC-3/S). Our model-driven analysis and experimental validations have unveiled a differential utilization of the long-chain fatty acids pool in both subpopulations. More specifically, our findings show an enhanced entry of long-chain fatty acids into the mitochondria in PC-3/M cells, while in PC-3/S cells, long-chain fatty acids are used as precursors of eicosanoid metabolism. The different utilization of long-chain fatty acids between subpopulations endows PC-3/M cells with a highly proliferative phenotype while enhances PC-3/S invasive phenotype. The present work provides a tool to unveil key metabolic nodes associated with tumor heterogeneity and highlights potential subpopulation-specific targets with important therapeutic implications.


  • Mitochondrial Protein UCP2 Controls Pancreas Development

    by Benjamin Broche, Selma Ben Fradj, Esther Aguilar, Tiphaine Sancerni, Matthieu Bénard, Fatna Makaci, Claire Berthault, Raphaël Scharfmann, Marie-Clotilde Alves-Guerra, Bertrand Duvillié

    The mitochondrial carrier UCP2 belongs to the family of the uncoupling proteins. Despite its name, it is now accepted that UCP2 is rather a metabolite transporter than an uncoupling protein. UCP2 can regulate oxidative stress and/or energetic metabolism. In rodents, UCP2 is involved in the control of alpha- and beta-cell mass as well as insulin- and glucagon-secretion. Our aim was to determine whether the effects of UCP2 observed on beta-cell mass have an embryonic origin. Thus, we used Ucp2 knock-out mice. We found an increased size of the pancreas in Ucp2-/- fetuses at E16.5, associated with a higher number of alpha- and beta-cells. This phenotype was caused by an increase of PDX1+ progenitor-cells. Perinatally, an increase in the proliferation of endocrine cells also participates to their expansion. Next, we analyzed the oxidative stress in the pancreata. We quantified an increased nuclear translocation of NRF2 in the mutant suggesting an increased production of ROS. Phosphorylation of AKT, a ROS-target, was also activated in the Ucp2-/- pancreata. Finally, administration of the antioxidant N-acetyl-L-cysteine to Ucp2-/- pregnant mice alleviated the effect of knocking-out UCP2 on pancreas development. Together, these data demonstrate that UCP2 controls pancreas development through the ROS-AKT signaling pathway.


  • Open Access

    MIDcor, an R-program for deciphering mass interferences in mass spectra of metabolites enriched in stable isotopes

    by Vitaly A. Selivanov, Adrián Benito, Anibal Miranda, Esther Aguilar, Ibrahim Halil Polat, Josep J. Centelles, Anusha Jayaraman, Paul W. N. Lee, Silvia Marin, Marta Cascante

    Tracing stable isotopes, such as 13C using various mass spectrometry (MS) methods provides a valuable information necessary for the study of biochemical processes in cells. However, extracting such information requires special care, such as a correction for naturally occurring isotopes, or overlapping mass spectra of various components of the cell culture medium. Developing a method for a correction of overlapping peaks is the primary objective of this study. Our computer program-MIDcor (free at https://github.com/seliv55/mid_correct) written in the R programming language, corrects the raw MS spectra both for the naturally occurring isotopes and for the overlapping of peaks corresponding to various substances. To this end, the mass spectra of unlabeled metabolites measured in two media are necessary: in a minimal medium containing only derivatized metabolites and chemicals for derivatization, and in a complete cell incubated medium. The MIDcor program calculates the difference (D) between the theoretical and experimentally measured spectra of metabolites containing only the naturally occurring isotopes. The result of comparison of D in the two media determines a way of deciphering the true spectra. (1) If D in the complete medium is greater than that in the minimal medium in at least one peak, then unchanged D is subtracted from the raw spectra of the labeled metabolite. (2) If D does not depend on the medium, then the spectrum probably overlaps with a derivatized fragment of the same metabolite, and D is modified proportionally to the metabolite labeling. The program automatically reaches a decision regarding the way of correction. For some metabolites/fragments in the case (2) D was found to decrease when the tested substance was 13C labeled, and this isotopic effect also can be corrected automatically, if the user provides a measured spectrum of the substance in which the 13C labeling is known a priori. Using the developed program improves the reliability of stable isotope tracer data analysis.


  • Open Access

    A key role for transketolase-like 1 in tumor metabolic reprogramming

    by Santiago Diaz-Moralli, Esther Aguilar, Silvia Marin, Johannes F. Coy, Mieke Dewerchin, Maciek R. Antoniewicz, Oscar Meca-Cortés, Leen Notebaert, Bart Ghesquière, Guy Eelen, et al.

    A key role for transketolase-like 1 in tumor metabolic reprogramming


  • Metabolic Reprogramming and Dependencies Associated with Epithelial Cancer Stem Cells Independent of the Epithelial-Mesenchymal Transition Program

    by Esther Aguilar, Igor Marin de Mas, Erika Zodda, Silvia Marin, Fionnuala Morrish, Vitaly Selivanov, Óscar Meca-Cortés, Hossain Delowar, Mònica Pons, Inés Izquierdo, et al.

    In solid tumors, cancer stem cells (CSCs) can arise independently of epithelial-mesenchymal transition (EMT). In spite of recent efforts, the metabolic reprogramming associated with CSC phenotypes uncoupled from EMT is poorly understood. Here, by using metabolomic and fluxomic approaches, we identify major metabolic profiles that differentiate metastatic prostate epithelial CSCs (e-CSCs) from non-CSCs expressing a stable EMT. We have found that the e-CSC program in our cellular model is characterized by a high plasticity in energy substrate metabolism, including an enhanced Warburg effect, a greater carbon and energy source flexibility driven by fatty acids and amino acid metabolism and an essential reliance on the proton buffering capacity conferred by glutamine metabolism. An analysis of transcriptomic data yielded a metabolic gene signature for our e-CSCs consistent with the metabolomics and fluxomics analyses that correlated with tumor progression and metastasis in prostate cancer and in 11 additional cancer types. Interestingly, an integrated metabolomics, fluxomics, and transcriptomics analysis allowed us to identify key metabolic players regulated at the post-transcriptional level, suggesting potential biomarkers and therapeutic targets to effectively forestall metastasis.


  • Cancer Cell Metabolism as New Targets for Novel Designed Therapies

    by Igor Marín de Mas, Esther Aguilar, Anusha Jayaraman, Ibrahim H Polat, Alfonso Martín-Bernabé, Rohit Bharat, Carles Foguet, Enric Milà, Balázs Papp, Josep J Centelles, et al.

    Metabolic processes are altered in cancer cells, which obtain advantages from this metabolic reprogramming in terms of energy production and synthesis of biomolecules that sustain their uncontrolle...


  • Open Access

    Cyclin-dependent kinases 4 and 6 control tumor progression and direct glucose oxidation in the pentose cycle

    by Miriam Zanuy, Antonio Ramos-Montoya, Oscar Villacañas, Nuria Canela, Anibal Miranda, Esther Aguilar, Neus Agell, Oriol Bachs, Jaime Rubio-Martinez, Maria Dolors Pujol, et al.

    Cyclin-dependent kinases CDK4 and CDK6 are essential for the control of the cell cycle through the G1 phase. Aberrant expression of CDK4 and CDK6 is a hallmark of cancer, which would suggest that CDK4 and CDK6 are attractive targets for cancer therapy. Herein, we report that calcein AM (the calcein acetoxymethyl-ester) is a potent specific inhibitor of CDK4 and CDK6 in HCT116 human colon adenocarcinoma cells, inhibiting retinoblastoma protein (pRb) phosphorylation and inducing cell cycle arrest in the G1 phase. The metabolic effects of calcein AM on HCT116 cells were also evaluated and the flux between the oxidative and non-oxidative branches of the pentose phosphate pathway was significantly altered. To elucidate whether these metabolic changes were due to the inhibition of CDK4 and CDK6, we also characterized the metabolic profile of a CDK4, CDK6 and CDK2 triple knockout of mouse embryonic fibroblasts. The results show that the metabolic profile associated with the depletion of CDK4, CDK6 and CDK2 coincides with the metabolic changes induced by calcein AM on HCT116 cells, thus confirming that the inhibition of CDK4 and CDK6 disrupts the balance between the oxidative and non-oxidative branches of the pentose phosphate pathway. Taken together, these results indicate that low doses of calcein can halt cell division and kill tumor cells. Thus, selective inhibition of CDK4 and CDK6 may be of greater pharmacological interest, since inhibitors of these kinases affect both cell cycle progression and the robust metabolic profile of tumors.


  • Differential nigral expression of bcl-2 protein family in the pure and common forms of Dementia with Lewy bodies: relevance for dopaminergic neuronal vulnerability

    by M. Saldaña, E. Aguilar, M. Bonastre, C. Marin

    We investigated whether bcl-2 protein family is involved in the pathogenesis of the dopaminergic neurodegeneration that occurs in Dementia with Lewy bodies (DLB). The expression of the proapoptotic protein bax and the antiapoptotic proteins bcl-2 and bcl-xL was investigated by Western blot in the pars compacta of the substantia nigra of pure and common DLB forms. No changes in the nigral expression levels of bax, bcl-2 and bcl-xL proteins were found between control and DLB pure cases. In the common DLB forms, nigral bcl-xL and bcl-2 proteins levels were significantly decreased in the DLB cases associated with a concomitant severe AD pathology (p < 0.05). An increase in nigral bcl-2 protein expression was observed in the DLB cases with a mild AD-associated pathology (p < 0.05). The present results are in agreement with previous observations indicating that DLB cases with severe AD pathology tend to show severe Lewy pathology suggesting that AD pathology might exacerbate Lewy pathology.